Slingshot members are tracking this event:

Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta (Exenatide Injection) in the United States

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Teva Pharmaceuticals USA has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca’s US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca’s BYETTA (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA described in Teva’s ANDA No. 205984 in the United States.The settlement allows Teva to commercialize its generic version of BYETTA(exenatide injection) in the U.S. beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 23, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Byetta, Exenatide Injection, Patent Litigation